HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Knee arthrography: comparison of iotrolan and ioxaglate sodium meglumine.

Abstract
Arthrographic image quality and relative morbidity resulting from use of the nonionic dimer iotrolan and the ionic dimer ioxaglate sodium meglumine were compared in a prospective double-blind study performed in 80 patients. Radiographs obtained 2, 5, 10, 15, 20, and 25 minutes after injection of contrast agent were graded for diagnostic quality. Relative morbidity was evaluated by the physician during the examination and later by the patient by means of a questionnaire. Iotrolan demonstrated better image quality on serial radiographs in knee joints without previous effusions. Most differences were not significant. The mean duration of diagnostic-quality images for both contrast media was about 23 minutes. Iotrolan and ioxaglate caused equal postprocedural pain (in about 50% of patients). Other types of discomfort were less when iotrolan was used, but the differences were not significant. With regard to long-lasting image quality, both contrast media are suitable for arthrography.
AuthorsW R Obermann, J L Bloem, J Hermans
JournalRadiology (Radiology) Vol. 173 Issue 1 Pg. 197-201 (Oct 1989) ISSN: 0033-8419 [Print] United States
PMID2781008 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Iodobenzoates
  • Triiodobenzoic Acids
  • iotrolan
  • Ioxaglic Acid
Topics
  • Adolescent
  • Adult
  • Aged
  • Double-Blind Method
  • Female
  • Humans
  • Iodobenzoates
  • Ioxaglic Acid (adverse effects)
  • Knee Joint (diagnostic imaging)
  • Male
  • Middle Aged
  • Radiography
  • Triiodobenzoic Acids (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: